<DOC>
	<DOCNO>NCT00133276</DOCNO>
	<brief_summary>The treatment chronic hepatitis C peginterferon ribavirin highly effective hamper peginterferon-induced psychopathology . Prevention peginterferon-induced psychopathology selective serotonin reuptake inhibitor ( SSRI 's ) ( paroxetine ) show effective patient treat interferon malignant disease . The aim study effect prophylactic treatment escitalopram ( another SSRI ) peginterferon-associated psychopathology patient treat peginterferon ribavirin chronic hepatitis C .</brief_summary>
	<brief_title>Prophylaxis Psychiatric Symptoms During Anti-HCV Treatment</brief_title>
	<detailed_description>The treatment chronic hepatitis C peginterferon ribavirin highly effective hamper peginterferon-induced psychopathology . Prevention peginterferon-induced psychopathology SSRI 's ( paroxetine ) show effective patient treat interferon malignant disease . The aim study effect prophylactic treatment escitalopram peginterferon-associated psychopathology patient treat peginterferon ribavirin chronic hepatitis C. Design : double blind , randomize control trial two arm , maximum 40 patient per arm . Patients , start peginterferon ribavirin , randomize receive escitalopram therapy 10 mg per day ( however , 5 mg first two week ) placebo . Study population selection : eighty patient receive peginterferon alfa-2a ( Pegasys 180 microgram ) ribavirin ( Copegus 400 mg twice daily ) include study . Aims study : 1. ass whether prophylactic treatment escitalopram avoids significantly occurrence peginterferon-induced psychiatric disturbance ; define increase two point observer-based rating scale reflect anxiety ( BAS : BriefAnxietyScale ) , loss concentration , depression loss impulse control ( Montgomery Asberg Depression Rating Scale : MADRS ) , 2. ass frequency major depression accord DSM IV criterion , escitalopram placebo-treated patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Male female patient 1870 year age Evidence chronic hepatitis C detectable serum HCVDNA Hepatitis C genotype 1,2,3 4 Indication antiviral therapy hepatitis C accord current clinical guideline Written informed consent History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study Abnormal thyroid stimulate hormone ( TSH ) Presence contraindication antiviral therapy Concurrent psychiatric axis I diagnosis accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM IV ) criterion , presence major depressive episode , bipolar disorder psychotic disorder . Concurrent use psychotropic drug MAOinhibitors , St John 's wort , Lithium 5 HTagonists antiepileptic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Peg-interferon</keyword>
	<keyword>Psychiatric side-effects</keyword>
</DOC>